ArticleTransfusion2026
Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBlood donor eligibility policies may exclude individuals based on medication use, but the donor health questionnaire may not reliably capture all prescriptions. This study evaluates the capacity of the compound adsorption device (CAD) within the INTERCEPT Blood System Pathogen Reduction Technology (PRT) for plasma to remove exogenous testosterone and high doses of two drugs on the FDA donor deferral list. STUDY DESIGN AND
methodsPlasma was manufactured from male whole blood donors undergoing testosterone replacement therapy (TRT) or whole blood donors with no medication history to be supplemented with supratherapeutic concentrations of apixaban, a common anticoagulant, and escalating doses of emtricitabine and tenofovir (FTC&TFV) to note any saturating effects of removal. Plasma units were treated with INTERCEPT PRT only using the amotosalen and CAD steps without photochemical activation. Quantitative assays analyzed pre- and post-CAD samples. Statistical analysis was performed using a Wilcoxon signed-rank test and one-way ANOVA.
resultsThe CAD reduced the mean free and total testosterone by 75% (pre-CAD 107.4, post-CAD 26.8 pg/mL) and 74% (pre-CAD 352.2, post-CAD 85.7 ng/mL), respectively. Apixaban was removed below the limit of detection (pre-CAD mean 420, post-CAD mean <23 ng/mL). Regardless of the initial dose, FTC&TFV concentrations decreased by 100% and 98%, respectively.
conclusionThe INTERCEPT PRT plasma kit CAD effectively removed multiple drug classes, suggesting a potential role in mitigating drug contamination in transfusable plasma products. These findings may support the reconsideration of some medication-based donor deferrals where the risk-benefit of donor safety and product efficacy favors collection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.